Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
N. Uchida (Kyoto, Japan), K. Fujita (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan). The clinical benefits of immune checkpoint inhibitors for thymic carcinomas. 2878

Member's Comments

No comment yet.

Related content which might interest you: The efficacy of immune checkpoint inhibitors in thoracic malignancies Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020 Year: 2021 Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019 The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019 Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 The role of STAT3 in T-cell responses during the development of NSCLC Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench Year: 2017 From ineffective tumor immune response to immunomodulation in lung cancer Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies? Year: 2017 Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study Source: ERJ Open Res, 6 (1) 00165-2019; 10.1183/23120541.00165-2019 Year: 2020 NTHi-induced inflammation activates the PD-1 immune checkpoint in the tumor microenvironment Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms Year: 2018 Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 The role of epithelial Pten in programmed cellular senescence during lung development Source: International Congress 2018 – Molecular and cellular determinants of the developing lung Year: 2018 The PD-1 immune checkpoint promotes lung damage in murine models of COPD-like inflammation Source: International Congress 2019 – Injury and repair: less is more Year: 2019 The role of NFATc1 in T cell responses during the development of NSCLC Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Long-term outcomes and prognostic factors for neuroendocrine G1 and G2 lung tumors Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer Source: International Congress 2019 – Lung cancer? Year: 2019 Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas Source: Eur Respir J 2004; 24: Suppl. 48, 557s Year: 2004